ARK Investment Management LLC reduced its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) by 9.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 302,124 shares of the company’s stock after selling 31,348 shares during the period. ARK Investment Management LLC owned approximately 1.45% of UroGen Pharma worth $1,607,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in URGN. Bank of America Corp DE boosted its position in shares of UroGen Pharma by 211.0% during the 1st quarter. Bank of America Corp DE now owns 128,317 shares of the company’s stock worth $1,118,000 after purchasing an additional 87,055 shares in the last quarter. State Street Corp boosted its position in shares of UroGen Pharma by 8.3% during the 1st quarter. State Street Corp now owns 548,241 shares of the company’s stock worth $4,775,000 after purchasing an additional 41,886 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of UroGen Pharma in the 1st quarter worth about $215,000. PDT Partners LLC purchased a new stake in shares of UroGen Pharma in the 1st quarter worth about $183,000. Finally, JPMorgan Chase & Co. boosted its position in shares of UroGen Pharma by 30.8% in the 1st quarter. JPMorgan Chase & Co. now owns 81,867 shares of the company’s stock worth $714,000 after buying an additional 19,280 shares in the last quarter.
UroGen Pharma Trading Down 2.4 %
UroGen Pharma stock opened at $8.51 on Tuesday. UroGen Pharma Ltd. has a 52 week low of $4.85 and a 52 week high of $19.66. The firm’s 50-day simple moving average is $8.24 and its 200 day simple moving average is $7.67.
UroGen Pharma Profile
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
- Get a free copy of the StockNews.com research report on UroGen Pharma (URGN)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.